Similarly, another phase Ib study was performed to evaluate the clinical efficiency of KN026, another bispecific antibody targeting HER2 (30) and KN046 (an anti-PD-L1 and anti-CTLA4 bispecific antibody) for metastatic GC and GEJ adenocarcinoma. This evidence concerns the gene CTLA4 and gastroesophageal junction adenocarcinoma.